The Procedure of Pricing is Changing
As of 2018 prices for drugs on the VED list will be established by the Federal Antimonopoly Service (FAS).
According to Andrey Kashevarov, Deputy Head of the Federal Antimonopoly Service (FAS), the Government has already approved the new procedure of pricing of VED drugs. Currently the Antimonopoly Agency is developing specific principles of pricing.
The declarative principle of pricing, implying that pricing offers, submitted by manufacturers of drugs from the VED list, are reviewed by FAS, will be abandoned. The maximum retail price for international non-proprietary name (INN) will be set by the antimonopoly agency.